IMDX (Insight Molecular Diagnostics) Cyclically Adjusted FCF per Share: $-7.41 (As of Mar. 2026)


IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $5.92
GF Value $1.26
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Cyclically Adjusted FCF per Share?

Insight Molecular Diagnostics IMDX +8.46% 49 Cyclically Adjusted FCF per Share is $-7.41 as of Mar. 2026. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Insight Molecular Diagnostics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.239. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-7.41 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-06-30), Insight Molecular Diagnostics's current stock price is $5.915. Insight Molecular Diagnostics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-7.41. Insight Molecular Diagnostics's Cyclically Adjusted Price-to-FCF of today is .


Insight Molecular Diagnostics  (NAS:IMDX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Insight Molecular Diagnostics Cyclically Adjusted FCF per Share Related Terms


Insight Molecular Diagnostics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics Cyclically Adjusted FCF per Share Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -8.00 -7.48

Insight Molecular Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.05 -7.74 -7.66 -7.48 -7.41

IMDX vs XGN, BDSX, BNR: Cyclically Adjusted FCF per Share Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics Cyclically Adjusted Price-to-FCF vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Cyclically Adjusted Price-to-FCF falls into.


IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insight Molecular Diagnostics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.239/330.2130*330.2130
=-0.239

Current CPI (Mar. 2026) = 330.2130.

Insight Molecular Diagnostics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1.418 241.018 -1.943
201609 -0.785 241.428 -1.074
201612 -1.811 241.432 -2.477
201703 -2.283 243.801 -3.092
201706 -2.259 244.955 -3.045
201709 -2.262 246.819 -3.026
201712 -2.130 246.524 -2.853
201803 -1.741 249.554 -2.304
201806 -2.054 251.989 -2.692
201809 -1.239 252.439 -1.621
201812 -1.207 251.233 -1.586
201903 -2.884 254.202 -3.746
201906 -1.097 256.143 -1.414
201909 -1.866 256.759 -2.400
201912 -2.276 256.974 -2.925
202003 -2.250 258.115 -2.878
202006 -2.264 257.797 -2.900
202009 -1.943 260.280 -2.465
202012 -1.873 260.474 -2.374
202103 -2.600 264.877 -3.241
202106 -1.931 271.696 -2.347
202109 -2.488 274.310 -2.995
202112 -1.619 278.802 -1.918
202203 -3.217 287.504 -3.695
202206 -2.188 296.311 -2.438
202209 -2.066 296.808 -2.299
202212 -1.760 296.797 -1.958
202303 -1.392 301.836 -1.523
202306 -0.844 305.109 -0.913
202309 -0.457 307.789 -0.490
202312 -0.535 306.746 -0.576
202403 -0.466 312.332 -0.493
202406 -0.479 314.175 -0.503
202409 -0.410 315.301 -0.429
202412 -0.320 315.605 -0.335
202503 -0.239 319.799 -0.247
202506 -0.208 322.561 -0.213
202509 -0.173 324.800 -0.176
202512 -0.219 324.054 -0.223
202603 -0.239 330.213 -0.239

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-7.41 mean?
Insight Molecular Diagnostics (IMDX) has a Cyclically Adjusted FCF per Share of $-7.41 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Insight Molecular Diagnostics and its competitors.
Is Insight Molecular Diagnostics' Cyclically Adjusted FCF per Share too high?
Insight Molecular Diagnostics' current Cyclically Adjusted FCF per Share is $-7.41. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Cyclically Adjusted FCF per Share compare to XGN and BDSX?
Insight Molecular Diagnostics' Cyclically Adjusted FCF per Share of $-7.41 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted FCF per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current Cyclically Adjusted FCF per Share is $-7.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.92 — trading 369.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-7.41. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Cyclically Adjusted FCF per Share is $-7.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.92 is trading 369.4% above its estimated GF Value™ of $1.26. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • Cyclically Adjusted FCF per Share: $-7.41
  • GF Value™: $1.26 vs. price of $5.92 (369.4% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.92
Price
$1.26
GF Value